Hughes Eric A 4

What Happened
Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of TEVA Pharmaceutical (TEVA), had 19,654 restricted share units (RSUs) vest on March 5, 2026. Those RSUs converted into 19,654 ordinary shares (reported as a derivative conversion). To cover tax withholding related to the vesting, Hughes sold 9,533 of those shares in open-market transactions for aggregate proceeds of $301,895 (weighted average price $31.67; individual sale prices ranged $31.26–$32.34). Net shares delivered to Hughes after the tax sale were 10,121 shares (19,654 vested − 9,533 sold).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
• Sale: 9,533 shares sold, weighted avg price $31.67, total proceeds $301,895 (prices ranged $31.26–$32.34).
• Vesting/conversion: 19,654 RSUs converted into ordinary shares (reported as derivative exercise/conversion).
• Net shares received from vesting after tax-sale: 10,121 shares.
• Notable footnotes: sale executed under a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F3); the sale represented shares required to be sold to cover tax withholding on vested RSUs (F4, F6). Each ordinary share may be represented by an ADS (F1).
• Shares owned after transaction: not specified in the filing.

Context

• This was not a market-timing purchase; it was a routine vesting of RSUs with a portion sold to cover taxes (common practice and not necessarily a signal about company prospects).
• The filing shows conversion of RSUs (derivative exercise/conversion code M) and an open-market sale (code S). The sale was executed under a pre-established 10b5-1 plan, which schedules trades irrespective of short-term company developments.